Clinical Trials on NOACs

Total 6 results

Cui Yimin

Unknown

Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants

Pharmacokinetics | Pharmacodynamics | Apixaban | Pharmacogenomics | Accurate Medication | Rivaroxaban | Novel Oral Anticoagulants | NOACs | Dabigatran

China
University Hospital Tuebingen
Heart and Diabetes Center North Rhine-Westphalia

Unknown

Specific PoC Testing of Coagulation in Patients Treated With DOAC 1 (SPOCT-DOAC 1)

Anticoagulation With NOAC

Germany
Cardioangiologisches Centrum Bethanien

Completed

Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices

Effect of NOAC on POCT
Peking University First Hospital

Not yet recruiting

Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II

Bleeding | Pharmacodynamics | Apixaban | Pharmacogenomics | Biomarker | Ticagrelor | Rivaroxaban | Novel Oral Anticoagulants | NOACs | Dabigatran | Edoxaban | RNA Profile

China
Centre Hospitalier Universitaire de Nīmes

Completed

Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur (ANTI_XA)

Femoral Fractures | Surgery | Direct Oral Anticoagulants (DOACs)

France
University of Erlangen-Nürnberg Medical School

Completed

Multicenter Analysis of Oral Anticoagulant-associated ICH - Part Two (RETRACE-II)

Anticoagulation Associated (VKA & NOAC) Intracerebral Hemorrhage

3

Subscribe